DIABELOOP CLOSED LOOP SYSTEM ALLOWS PATIENTS WITH DIABETES TYPE 1 (DT1) TO PRACTICE PHYSICAL ACTIVITY (PA) WITHOUT INCREASING HYPOGLYCAEMIC RISK

Session Name
ARTIFICIAL PANCREAS
Session Type
E-POSTER VIEWING (EXHIBITION HOURS)
Date
20.02.2020, Thursday
Session Time
09:30 - 15:30
Channel
E-Poster Area
Lecture Time
09:39 - 09:40
Presenter
  • Sylvia Franc, France
Authors
  • Sylvia Franc, France
  • Pierre-Yves Benhamou, France
  • Sophie Borot, France
  • Lucy Chaillous, France
  • Brigitte Delemer, France
  • Maeva Doron, France
  • Bruno Guerci, France
  • Helene Hanaire, France
  • Erik Huneker, France
  • Nathalie Jeandidier, France
  • Alfred Penfornis, France
  • Eric Renard, France
  • Yves Reznik, France
  • Pauline Schaepelynck, France
  • Chantal Simon, France
  • Charles Thivolet, France
  • Guillaume Charpentier, France

Abstract

Background and Aims

Is the closed-loop system DBLG1 able to reduce hypoglycaemic risk in case of physical activity (PA) in patients with T1D ?

Methods

We conducted a 3 months crossover trial where patients were using either a hybrid monohormonal system (CellNovo® or Kaleido® pump and Dexcom G5® sensor) using MPC-based algorithm and centralized remote monitoring, or an open loop. Patients were encouraged to practice PA, but it was recommended to announce in advance to the system, the occurrence, intensity and duration of PA.

Results

68 patients (27 men, age 47.2±13.4 years, HbA1c 7.6±0.9%, were included, and 63 were analyzed (mITT). The median number of PA events per patient during the study was 10, median duration 60 mn, intensity light (40%), medium (42%) intense (19%). Time in range (TIR) (70-180 mg/dl) was similar with (68.2 ± 1.1%) or without (69.1 ± 1.1%) PA, as was TIR<70 mg/dl during the day (2.3 ± 0.2% v 2.4 ± 0.2%) or the night (1.2 ± 0.2% v 1.6 ± 0.2%). TIR<70 mg/dl was 1.9, 2.1, 1.9 and 2.0% following PA duration of <30mn, 30 to 60, 60 to 90 or >90 mn, and 1.6, 2.2 or 2.2% following light, medium or intense PA. TIR<70 mg/dl was 2.2, 2.3 and 1.7% with announcement <30, 30 to 60 and > 60 mn before PA and 2.3% with none.

Conclusions

The Diabeloop’s DBLG1 System is able to maintain good glycemic control even in the case of PA practice. Duration, intensity or PA announcement demonstrated modest impact.

Hide